Business ❯ Pharmaceuticals

Drug Manufacturers

Pricing Strategies Eli Lilly Corporate Leadership Market Impact Mallinckrodt Pharmaceuticals Novo Nordisk Catalent Market Dynamics Covid-19 Treatments Negotiation Strategies Kenvue EMD Serono Negotiations Cipla Major Companies Pricing Agreements Market Agreements GLP-1 Drugs Market Competition

CMS Unveils Voluntary BALANCE Program to Lower GLP-1 Costs for Medicare and Medicaid

The program pairs discounted drug access with no-cost lifestyle support through a phased rollout beginning in 2026.

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers

White House Secures Nine More Drugmaker Pacts on MFN Pricing as TrumpRx Nears Launch

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs

Medicare Sets 2027 Prices for 15 High-Cost Drugs, Including Ozempic

Lilly, Novo Nordisk Reject Mangoceuticals’ Claimed GLP-1 Partnership as Shares Sink

White House Clinches GLP-1 Price Deal as Lilly Sets Zepbound and Pill Pricing

Kenvue Urges HHS to Reject Autism Link to Prenatal Tylenol in Private Meeting